Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in multiple publications regarding the MEDTECH Act.
Following is an excerpt from mHealth News:
Bradley Merrill Thompson, an attorney with the Washington, D.C.-based firm of Epstein Becker Green and spokesman for the CDS Coalition, said the new bill "moves the ball forward" in that it clarifies what has once been a long and complicated bill. But he said the new bill is still "very complicated and not nearly as much fun to read."
"You have to read it carefully to understand whether we’re talking about something that is regulated or something that is not regulated," he told mHealth News.
"I think the bill does a nice job of striking the balance where software that analyzes medical information, to help a doctor, but presents the information in a way that does not force the doctor to rely on the software, would be unregulated by FDA," Thompson concluded. "That’s the right approach."
Related reading:
- Politico, 4/28/2015
- mHealth News, 4/28/2015
- FierceHealthIT, 4/28/2015
- iHealthBeat, 4/28/2015
- BNA Insights, 4/28/2015
- HealthData Management, 4/28/2015
- BNA Highlights, 4/28/2015
- FDA Week, 4/28/2015
- BNA Snapshot, 4/28/2015
